Xinxin(饶欣欣) completed her Master’s degree in radiation medicine at Shanghai Medical School, Fudan University. She joined the laboratory as PhD candidate in Oct. 2021. She is currently interested in using multimodality approaches including genome-wide CRISPR/Cas9 screening and epigenome analysis in patient-derived organoids and tumor samples to discover and understand the critical factors which determine the treatment response in breast cancer.